4.6 Article

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer A Multicenter International Cohort Study

期刊

JAMA ONCOLOGY
卷 7, 期 12, 页码 1856-1861

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamaoncol.2021.4960

关键词

-

类别

资金

  1. National Cancer Institute [1F32CA254070-01]
  2. National Institute on Aging [R03AG064374]
  3. Ohio State University Comprehensive Cancer Center
  4. OSU K12 Training Grant for Clinical Faculty Investigators [K12 CA133250]
  5. REDCap project
  6. Ohio State University Center for Clinical and Translational Science [UL1TR002733]
  7. Italian Ministry of Health [Co-2016-02361470]
  8. Compagnia di San Paolo [2017.0529]
  9. Wellcome Trust Strategic Fund
  10. Imperial Experimental Cancer Medicine Centre
  11. Cancer Research UK Imperial Centre
  12. Imperial College Healthcare NHS Trust Tissue Bank
  13. Imperial College BRC
  14. Dana-Farber/Harvard Cancer Center Kidney SPORE [2P50CA101942-16]
  15. Kohlberg Chair at Harvard Medical School
  16. Trust Family
  17. Loker Pinard Funds for Kidney Cancer Research at DFCI
  18. Conquer Cancer Foundation, National Cancer Institute
  19. Lung Cancer Initiative of North Carolina
  20. [5P30CA006516-56]

向作者/读者索取更多资源

An international multicenter retrospective study showed that treatment with ICIs may be effective and generally well tolerated among older patients with cancer, although ICI discontinuation due to irAEs was more frequent with increasing age.
IMPORTANCE Geriatric (aged >= 80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related adverse events (irAEs), which may be particularly associated with morbidity in this population. OBJECTIVE To provide insight into the clinical outcomes and safety of ICIs among geriatric patients (aged >= 80 years) with cancer. DESIGN, SETTING, AND PARTICIPANTS A Multicenter, international retrospective study of 928 geriatric patients with different tumors treated with single-agent ICIs between 2010 to 2019 from 18 academic centers in the US and Europe. Analyses were conducted from January 2021 to April 2021. MAIN OUTCOMES AND MEASURES Clinical outcomes and irAE patterns in geriatric patients treated with single-agent ICIs. RESULTS Median (range) age of the 928 patients at ICI initiation was 83.0 (75.8-97.0) years. Most patients (806 [86.9%]) were treated with anti-programmed cell death 1 therapy. Among the full cohort, the 3 most common tumors were non-small cell lung cancer (NSCLC, 345 [37.2%]), melanoma (329 [35.5%]), and genitourinary (GU) tumors (153 [16.5%]). Objective response rates for patients with NSCLC, melanoma, and GU tumors were 32.2%, 39.3%, and 26.2%, respectively. Median PFS and OS, respectively, were 6.7 and 10.9 months (NSCLC), 11.1 and 30.0 months (melanoma), and 6.0 and 15.0 months (GU). Within histologically specific subgroups (NSCLC, melanoma, and GU), clinical outcomes were similar across age subgroups (aged <85 vs >= 85 years). Among all 928 patients, 383 (41.3%) experienced >= 1 irAE(s), including 113 (12.2%) that were reported to be grade (G) 3 to 4 based on Common Terminology Criteria for Adverse Events (version 5.0). The median time to irAE onset was 9.8 weeks; 219 (57%) occurred within the first 3 months after ICI initiation. Discontinuation of treatment with ICIs owing to irAEs occurred in 137 (16.1%) patients. There was no significant difference in the rate of irAEs among patients aged younger than 85, 85 to 89, and 90 years or older. Despite the similar rate of G3 or higher irAEs, ICIs were discontinued owing to irAEs more than twice as often among patients aged 90 years or older compared with patients younger than 90 years (30.9% vs 15.1%, P =.008). CONCLUSIONS AND RELEVANCE The findings of this international cohort study suggest that treatment with ICIs may be effective and generally well tolerated among older patients with cancer, though ICI discontinuation owing to irAEs was more frequent with increasing age.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据